/Charles%20River%20Laboratories%20International%20Inc_%20logo-%20by%20IgorGolovniov%20via%20Shutterstock.jpg)
Valued at a market cap of $7.3 billion, Charles River Laboratories International, Inc. (CRL) provides drug discovery, non-clinical development, and safety testing services worldwide. Headquartered in Wilmington, Massachusetts, the company operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).
Companies valued between $2 billion and $10 billion are generally classified as “mid-cap stocks," and Charles River Laboratories fits this criterion perfectly. The company helps pharmaceutical and biotechnology companies, government agencies, and leading academic institutions around the globe accelerate their research and drug development efforts by providing essential products and services.
